CancerCare webinar: Update on Advanc... - SHARE Ovarian Can...

SHARE Ovarian Cancer Support

2,791 members992 posts

CancerCare webinar: Update on Advanced Ovarian Cancer

GwenHP profile image
1 Reply

I wanted to make sure all of you knew about an upcoming program offered by CancerCare on May 2nd from 1:30-2:20 Eastern Time. You can register by going to tinyurl.com/lf25z6s . You can either listen via phone or online as a webcast. The topics covered:

Overview of Ovarian Cancer

Therapy Options for Recurrent & Advanced Ovarian Cancer

New Treatment Approaches & Follow-Up Care

The Role of Personalized Medicine in Informing Treatment Decisions

How BRCA Testing May Impact Your Care

The Role of the Pathologist: The Importance of Diagnostic Testing in Advanced Ovarian Cancer

Clinical Trial Updates

Controlling Side Effects, Symptoms, Discomfort & Pain

Talking with Your Treatment Team about Your Quality-of-Life Concerns

Questions for Our Panel of Experts

Written by
GwenHP profile image
GwenHP
To view profiles and participate in discussions please or .
Read more about...
1 Reply
eileen_alberti profile image
eileen_alberti

Missed the actual date but caught it on replay. Very informative and a must for every newbie. We need more of these. The doctors took the time to explain a lot. Thanks for the heads up about this valuable seminar. Blessings, Eileen

Not what you're looking for?

You may also like...

Rare Ovarian Cancers Webinar

Update! The recording from the webinar is now available and can be viewed here:...

Ovarian cancer drug delivers ‘very promising’ results in early trial

Here's an article about a promising new drug for women with advanced ovarian cancer:...

Stage 4 advance ovarian cancer

Hi every one My wife was diagnosed with stage 4 advanced ovarian cancer. She did 4 chemothrapy and...

Cheryl: Stage I Ovarian Cancer

*This is a story from a SHARE peer that was shared originally here:...

Ovarian Cancer Screening Tests?

Did any of you hear that the FDA recently issued a warning against the use of products marketed as...